



Derek Richard Clements

Postdoctoral Scholar, Microbiology and Immunology

Bio

PROFESSIONAL EDUCATION

- Doctor of Philosophy, Dalhousie University (2018)
- Bachelor of Science, Dalhousie University (2012)

STANFORD ADVISORS

- Juliana Idoyaga, Postdoctoral Faculty Sponsor

Publications

PUBLICATIONS

- **Alveolar macrophages and epithelial cells: The art of living together.** *The Journal of experimental medicine*
Clements, D., Idoyaga, J.
2021; 218 (10)
- **Skin dendritic cells in melanoma are key for successful checkpoint blockade therapy.** *Journal for immunotherapy of cancer*
Prokopi, A., Tripp, C. H., Tummers, B., Hornsteiner, F., Spoeck, S., Crawford, J. C., Clements, D. R., Efremova, M., Hutter, K., Bellmann, L., Cappellano, G., Cadiha, B. L., Kobold, et al
2021; 9 (1)
- **Trial Watch: oncolytic viro-immunotherapy of hematologic and solid tumors** *Oncimmunology*
Pol, J. G., Levesque, S., Workenhe, S. T., Gujar, S., Le Boeuf, F., Clements, D. R., Fahrner, J., Fend, L., Bell, J. C., Mossman, K. L., Fucikova, J., Spisek, R., Zitvogel, et al
2018
- **Quantitative Temporal in Vivo Proteomics Deciphers the Transition of Virus-Driven Myeloid Cells into M2 Macrophages.** *Journal of proteome research*
Clements, D. R., Murphy, J. P., Sterea, A. n., Kennedy, B. E., Kim, Y. n., Helson, E. n., Almasi, S. n., Holay, N. n., Konda, P. n., Paulo, J. A., Sharif, T. n., Lee, P. W., Weekes, et al
2017; 16 (9): 3391–3406
- **All that glitters is not gold: the need to consider desirable and undesirable immune aspects of oncolytic virus therapy** *ONCOIMMUNOLOGY*
Clements, D. R., Kim, Y., Gujar, S. A., Lee, P. W.
2016; 5 (1)
- **Dendritic Cells in Oncolytic Virus-Based Anti-Cancer Therapy** *VIRUSES-BASEL*
Kim, Y., Clements, D. R., Sterea, A. M., Jang, H. W., Gujar, S. A., Lee, P. W.
2015; 7 (12): 6506-6525
- **Newly Recruited CD11b(+), GR-1(+), Ly6C(high) Myeloid Cells Augment Tumor-Associated Immunosuppression Immediately following the Therapeutic Administration of Oncolytic Reovirus** *JOURNAL OF IMMUNOLOGY*
Clements, D. R., Sterea, A. M., Kim, Y., Helson, E., Dean, C. A., Nunokawa, A., Coyle, K. M., Sharif, T., Marcato, P., Gujar, S. A., Lee, P. W.

2015; 194 (9): 4397-4412

- **Gemcitabine enhances the efficacy of reovirus-based oncotherapy through anti-tumour immunological mechanisms** *BRITISH JOURNAL OF CANCER*
Gujar, S. A., CLEMENTS, D., Dielschneider, R., Helson, E., Marcato, P., Lee, P. W.
2014; 110 (1): 83-93
- **Two is better than one Complementing oncolytic virotherapy with gemcitabine to potentiate antitumor immune responses** *ONCOIMMUNOLOGY*
Gujar, S. A., Clements, D., Lee, P. W.
2014; 3 (1)
- **Reovirus in cancer therapy: an evidence-based review.** *Oncolytic virotherapy*
Clements, D., Helson, E., Gujar, S. A., Lee, P. W.
2014; 3: 69-82
- **Quantitative Proteome Responses to Oncolytic Reovirus in GM-CSF- and M-CSF-Differentiated Bone Marrow-Derived Cells.** *Journal of proteome research*
Giacomantonio, M. A., Sterea, A. M., Kim, Y., Paulo, J. A., Clements, D. R., Kennedy, B. E., Bydoun, M. J., Shi, G., Waisman, D. M., Gygi, S. P., Giacomantonio, C. A., Murphy, J. P., Gujar, et al
2020; 19 (2): 708-718
- **Single Amino Acid Differences between Closely Related Reovirus T3D Lab Strains Alter Oncolytic Potency In Vitro and In Vivo** *JOURNAL OF VIROLOGY*
Mohamed, A., Clements, D. R., Gujar, S. A., Lee, P. W., Smiley, J. R., Shmulevitz, M.
2020; 94 (4)
- **Inhibition of Pyruvate Dehydrogenase Kinase Enhances the Antitumor Efficacy of Oncolytic Reovirus.** *Cancer research*
Kennedy, B. E., Murphy, J. P., Clements, D. R., Konda, P., Holay, N., Kim, Y., Pathak, G. P., Giacomantonio, M. A., Hiani, Y. E., Gujar, S.
2019; 79 (15): 3824-3836
- **Therapy-Induced MHC I Ligands Shape Neo-Antitumor CD8 T Cell Responses during Oncolytic Virus-Based Cancer Immunotherapy** *JOURNAL OF PROTEOME RESEARCH*
Murphy, J., Kim, Y., Clements, D. R., Konda, P., Schuster, H., Kowalewski, D. J., Paulo, J. A., Cohen, A. M., Stevanovic, S., Gygi, S. P., Gujar, S.
2019; 18 (6): 2666-2675
- **The lysosomal TRPML1 channel regulates triple negative breast cancer development by promoting mTORC1 and purinergic signaling pathways** *CELL CALCIUM*
Xu, M., Almasi, S., Yang, Y., Yan, C., Sterea, A., Syeda, A., Shen, B., Derek, C., Huang, P., Gujar, S., Wang, J., Zong, W., Trebak, et al
2019; 79: 80-88
- **Multiplexed Relative Quantitation with Isobaric Tagging Mass Spectrometry Reveals Class I Major Histocompatibility Complex Ligand Dynamics in Response to Doxorubicin** *ANALYTICAL CHEMISTRY*
Murphy, J., Yu, Q., Konda, P., Paulo, J. A., Jedrychowski, M. P., Kowalewski, D. J., Schuster, H., Kim, Y., Clements, D., Jain, A., Stevanovic, S., Gygi, S. P., Mancias, et al
2019; 91 (8): 5106-5115
- **TRPM2 ion channel promotes gastric cancer migration, invasion and tumor growth through the AKT signaling pathway.** *Scientific reports*
Almasi, S., Sterea, A. M., Fernando, W., Clements, D. R., Marcato, P., Hoskin, D. W., Gujar, S., El Hiani, Y.
2019; 9 (1): 4182
- **TRPM2 Silencing Causes G2/M Arrest and Apoptosis in Lung Cancer Cells via Increasing Intracellular ROS and RNS Levels and Activating the JNK Pathway.** *Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology*
Almasi, S., Long, C. Y., Sterea, A., Clements, D. R., Gujar, S., El Hiani, Y.
2019; 52 (4): 742-57
- **RTN4 Knockdown Dysregulates the AKT Pathway, Destabilizes the Cytoskeleton, and Enhances Paclitaxel-Induced Cytotoxicity in Cancers** *MOLECULAR THERAPY*
Pathak, G. P., Shah, R., Kennedy, B. E., Murphy, J., Clements, D., Konda, P., Giacomantonio, M., Xu, Z., Schlaepfer, I. R., Gujar, S.
2018; 26 (8): 2019-33
- **Epigenetic Silencing of TAP1 in Aldefluor+ Breast Cancer Stem Cells Contributes to Their Enhanced Immune Evasion.** *Stem cells (Dayton, Ohio)*
Sultan, M., Vidovic, D., Paine, A. S., Huynh, T. T., Coyle, K. M., Thomas, M. L., Cruickshank, B. M., Dean, C. A., Clements, D. R., Kim, Y., Lee, K., Gujar, S. A., Weaver, et al

2018; 36 (5): 641-654

- **Surfen, a proteoglycan binding agent, reduces inflammation but inhibits remyelination in murine models of Multiple Sclerosis.** *Acta neuropathologica communications*
Warford, J. R., Lamport, A. C., Clements, D. R., Malone, A., Kennedy, B. E., Kim, Y., Gujar, S. A., Hoskin, D. W., Easton, A. S.
2018; 6 (1): 4
- **The NAD⁺ Salvage Pathway Supports PHGDH-Driven Serine Biosynthesis** *Cell Reports*
Murphy, J. P., Giacomantonio, M., Paulo, J. A., Everley, R. A., Kennedy, B. E., Pathak, G. P., Clements, D. R., Kim, Y., Dai, C., Sharif, T., Gygi, S. P., Gujar, S.
2018
- **MHC-I Ligand Discovery Using Targeted Database Searches of Mass Spectrometry Data: Implications for T-Cell Immunotherapies** *JOURNAL OF PROTEOME RESEARCH*
Murphy, J. P., Konda, P., Kowalewski, D. J., Schuster, H., Clements, D., Kim, Y., Cohen, A. M., Sharif, T., Nielsen, M., Stevanovic, S., Lee, P. W., Gujar, S.
2017; 16 (4): 1806-1816
- **Autophagic homeostasis is required for the pluripotency of cancer stem cells** *AUTOPHAGY*
Sharif, T., Martell, E., Dai, C., Kennedy, B. E., Murphy, P., Clements, D. R., Kim, Y., Lee, P. W., Gujar, S. A.
2017; 13 (2): 264-284
- **Breast cancer subtype dictates DNA methylation and ALDH1A3-mediated expression of tumor suppressor RARRES1** *ONCOTARGET*
Coyle, K. M., Murphy, J. P., Vidovic, D., Vaghar-Kashani, A., Dean, C. A., Sultan, M., Clements, D., Wallace, M., Thomas, M. L., Hundert, A., Giacomantonio, C. A., Helyer, L., Gujar, et al
2016; 7 (28): 44096-44112
- **The NAD(+) salvage pathway modulates cancer cell viability via p73** *CELL DEATH AND DIFFERENTIATION*
Sharif, T., Ahn, D., Liu, R., Pringle, E., Martell, E., Dai, C., NUNOKAWA, A., Kwak, M., CLEMENTS, D., Murphy, J. P., Dean, C., Marcato, P., McCormick, et al
2016; 23 (4): 669-680
- **Aldehyde dehydrogenase 1A3 influences breast cancer progression via differential retinoic acid signaling.** *Molecular oncology*
Marcato, P., Dean, C. A., Liu, R., Coyle, K. M., Bydoun, M., Wallace, M., Clements, D., Turner, C., Mathenge, E. G., Gujar, S. A., Giacomantonio, C. A., Mackey, J. R., Godbout, et al
2015; 9 (1): 17-31
- **Core Needle Biopsy of Breast Cancer Tumors Increases Distant Metastases in a Mouse Model** *NEOPLASIA*
Mathenge, E. G., Dean, C. A., Clements, D., Vaghar-Kashani, A., Photopoulos, S., Coyle, K. M., Giacomantonio, M., Malueth, B., Nunokawa, A., Jordan, J., Lewis, J. D., Gujar, S. A., Marcato, et al
2014; 16 (11): 950-960
- **The NAD(+) synthesizing enzyme nicotinamide mononucleotide adenylyltransferase 2 (NMNAT-2) is a p53 downstream target** *CELL CYCLE*
Pan, L., Ahn, D., Sharif, T., Clements, D., Gujar, S. A., Lee, P. W.
2014; 13 (6): 1041-1048
- **Gemcitabine-mediated tumour regression and p53-dependent gene expression: implications for colon and pancreatic cancer therapy** *CELL DEATH & DISEASE*
Hill, R., Rabb, M., Madureira, P. A., CLEMENTS, D., Gujar, S. A., Waisman, D. M., Giacomantonio, C. A., Lee, P. W.
2013; 4
- **Multifaceted Therapeutic Targeting of Ovarian Peritoneal Carcinomatosis Through Virus-induced Immunomodulation** *MOLECULAR THERAPY*
Gujar, S., Dielschneider, R., Clements, D., Helson, E., Shmulevitz, M., Marcato, P., Pan, D., Pan, L., Ahn, D., Alawadhi, A., Lee, P. W.
2013; 21 (2): 338-347